Basement membranes are structures containing both collagenous and non-collagenous glycoproteins. Laminin, a large non-collagenous glycoprotein component of basement membranes was isolated by Timpl et al. ' After digestion with pepsin two distinct antigenic fragments of the protein, laminin P1 and P2, can be isolated. 2 The morphological feature which characterises diabetic microangiopathy is a thickened capillary basement membrane. 3 In animal models of diabetes mellitus serum concentrations of basement membrane components such as type IV collagen and laminin were found to be raised.45 Thus we investigated whether serum concentrations of the pepsin resistant laminin P1 might be a valuable indicator of microangiopathic complications in diabetic patients.
Accepted for publication 7 In all diabetic patients and control subjects serum concentrations of the pepsin resistant fragment laminin P1 were measured by a commercial radioimmunoassay (RIAgnost laminin, Behring, Marburg/ Lahn, West Germany).
Intraassay and interassay coefficients of variation were 6 3% and 6 1%, respectively. Plasma creatinine was measured by an American Monitor Parallel Analyser; HbAIC by high pressure liquid cromatography (Biorad). The collection period of urinary albumin excretion and urinary protein excretion was 24 hours. Urinary albumin excretion was determined by a commercial radioimmunoassay (Pharmacia, Albumin RIA 100, Uppsala, Sweden). Urinary The presence or absence ofdiabetic retinopathy was assessed by both fundoscopy and fluorescein angiography.
All the data in the text, the table, and the figures are presented as the mean (SEM) and the 95% confidence interval (95% CI).7 Analysis of variance, unpaired Student's t test, and Pearson correlation coefficients were used for statistical evaluation. P values below 0 05 were considered to be significant.
Results
Figs 1 and 2 show the serum laminin P1 concentrations in diabetic patients and control subjects. Both in types I and II diabetic patients the analysis of variance showed significantly different serum laminin P1 concentrations in the various stages of diabetic nephropathy (p < 0-0001). Laminin P1 concentrations in type I diabetic patients without nephropathy Serum laminin P1 in diabetic patients with nephropathy 931 -0 18 to 0.04 U/mI and from -0-21 to 0.07 U/mI, respectively). In contrast, type I diabetic patients with macroproteinuria (1 -63 (0-11) U/mi) or with renal insufficiency (2.11 (0.29) U/mi) had significantly increased serum laminin concentrations when compared with those of control subjects (95% CI from 0-08 to 046 U/mI and from 045 to 1 05 U/mI, respectively). Similarly, as in type I diabetic patients, serum laminin concentrations in type II diabetic patients without diabetic nephropathy (1.37 (0.04) U/ ml) and with microalbuminuria (1.49 (0.03) U/mi) were comparable with those of the control subjects (1 45 (0.09) U/ml; 95% CI from -027 to 0-11 U/mI and from -0 13 to 0.21 U/mI, respectively); type II diabetic patients with macroproteinuria (1-88 (0.10) U/mi) and with renal insufficiency (1-90 (0-16) U/mi) had significantly increased serum laminin concentrations (95% CI from 0-15 to 0-71 U/mI and from 0 12 to 0-78 U/mI, respectively).
Among the patients without diabetic nephropathy serum laminin concentrations were comparable in patients with advanced diabetic retinopathy-type I (n = 8) and type II diabetic patients (n = 5) and in patients without diabetic retinopathy (10 type I and 13 type II diabetic patients) (in type I diabetic patients:
1 29 (0-11) v 1-37 (0.11) U/ml; 95% CI from -039 to 0-23 U/ml); in type II diabetic patients: 1-17 (0.11) v 1 19 (0.07) U/ml; 95% CI from -0-28 to 0-24 U/ml).
Both in types I and II diabetic patients a significant positive correlation between serum laminin P1 and serum creatinine concentrations could be found, (r = 041; p < 0.0001 and r = 0.33; p < 0.0001, respectively).
Discussion
Our data show that serum concentrations of laminin P1 in type I as well as in type II diabetes mellitus are raised in advanced diabetic nephropathy; serum laminin concentrations in patients without diabetic nephropathy and with microalbuminuria are comparable with those of the control subjects. Serum laminin P1 concentrations were not found to be influenced by the presence or absence of diabetic retinopathy.
Risteli and coworkers studied serum concentrations of the basement membrane components 7-S collagen and laminin P2 in diabetic rats treated with streptozotocin.4 Both 7-S collagen and laminin P2 were raised in these rats when compared with non-diabetic control rats. Treatment with insulin prevented the increase of 7-S collagen in the serum but did not completely normalise the laminin P2 concentrations. The authors concluded that the analysis of these antigens in serum may give useful information on the metabolism of basement membranes. Hogemann et al reported that serum laminin concentrations in patients with diabetic microvascular lesions were not significantly different from patients without clinical signs of microangiopathy. 8 The disagreement with our data might be explained by the fact that Hogemann et al did not differentiate between patients with retinopathy and nephropathy.
Recently, Karttunen and coworkers9 showed that the concentration of laminin in kidney cortex in a diabetic patient with nephropathy was much higher than in the controls, whereas laminin concentrations in kidney cortex offour diabetic patients without signs of nephropathy did not differ from non-diabetic subjects. These data are consistent with our findings of increased serum laminin P1 concentrations in advanced diabetic nephropathy and normal laminin P1 concentrations in patients without diabetic nephropathy. It may be speculated that raised serum laminin concentrations in advanced diabetic nephropathy might reflect an increased synthesis or a disturbed metabolism of basement proteins.
Early detection of diabetic nephropathy seems to have important clinical consequences as recent studies suggest that tight metabolic and blood pressure control might retard progression of incipient diabetic renal damage.'"'2 Mogensen et al showed that microalbuminuria predicts the development of diabetic nephropathy.'3 In our study serum laminin P1 concentrations in diabetic patients with microalbuminuria were not increased compared with those of control subjects, indicating that serum laminin P1 concentrations are not a sensitive marker for incipient renal damage. The determination of serum laminin P1 concentrations, however, might be clinically applied as an additional non-invasive variable in studying the clinical course or the effect of therapeutic intervention in advanced diabetic nephropathy.
